Negative resultsPlasma levels of beta-amyloid (1–42) in Alzheimer's disease and mild cognitive impairment
Section snippets
Methods
The 324 study subjects were recruited at neurology clinics located in Italy and Switzerland. A diagnosis of probable AD was made by exclusion according to NINCDS-ADRDA criteria [3]. Memory impairment was the only cognitive symptoms for the MCI group. The control group was not demented and had MMSE score ≥28. The plasma concentration of beta-amyloid 1–42 was measured by a specific sandwich-type enzyme-linked immunoassorbent assay ELISA (Innogenetics Ltd., Belgium). APOE genotype was determined
Results and comments
The AD, MCI and CT groups had similar age, sex and educational attainment; the frequency of APOE4 carriers was expectedly group-specific (AD > MCI > CT) (Table 1).
The AD group had lower mean plasma beta-amyloid 1–42: 38, 54, 52 (p < 0.01) (Fig. 1). For AD, patients levels was unrelated to age, sex or APOE status. No trend was found in relation to severity of disease as measured by MMSE score (Fig. 2, also see Supplemental material) or clinical dementia rating (CDR) (data not shown). For the 20 cases
Acknowledgements
The study was supported by the Project ‘Ruolo della Nicastrina nell’eziopatogenesi dell’Alzheimer Familiare’, Ministry of Health of Italy and Monzino Foundation (no profit foundation), Milan, Italy. MP is a recipient of a fellowship from “Associazione Ricerca sulle Demenze”, Milan, Italy (ARD).
References (4)
- et al.
Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses?
Arch Neurol
(2003) - et al.
Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease
J Neurosci
(2001)
Cited by (99)
Recent advances in electrochemical biosensors for the detection of Aβ42, a biomarker for Alzheimer disease diagnosis
2023, TrAC - Trends in Analytical ChemistryHeme/Cu-oxygen intermediates of amyloid β peptides associated with Alzheimer's disease
2023, Advances in Inorganic ChemistryThe pleiotropic beneficial intervention of olive oil intake on the Alzheimer's disease onset via fibrinolytic system
2021, Experimental GerontologyCitation Excerpt :For this reason, we further examined the effect of EVOO on AD biomarkers (Αβ and p-tau), with a view to detecting an overall amelioration of AD symptoms via the regard of fibrinolysis-improvement. Our data in serum come in agreement with the report that plasma Aβ levels are obviously reduced in the different dementia stages of AD, and reduction in levels of Aβ1-40 and of Aβ1-42 (Pesaresi et al., 2006; Rembach et al., 2013) is associated with cognitive decline, suggesting that noteworthy alterations in Aβ metabolism happen later in the periphery, in comparison with the brain (Janelidze et al., 2016a). In our research the annual therapy with EVOO of the MCI patients group, molded a refinement as far as amyloid detecting levels.